BioMarin’s Strategic Expansion: Alesta Acquisition Signals Pivot Toward Broader Rare Disease Markets
BioMarin’s Strategic Expansion: Alesta Acquisition Signals Pivot Toward Broader Rare Disease Markets
By Jonathan Gardner | August 18, 2026 In a move that underscores its aggressive pursuit of clinical-stage...
